What is the fair value of TMO?

Based on inv-AI’s institutional-grade analysis, the 12-month fair value estimate for Thermo Fisher Scientific Inc. (TMO) is $519 (range: $430–$608). Confidence level: MEDIUM.

Is TMO overvalued or undervalued?

Thermo Fisher Scientific Inc. (TMO) is rated Slight Underpriced by inv-AI. The current price is $490 versus a mid fair value of $519, implying +5.9% upside.

What is the TMO price target for 2026?

inv-AI’s 2026 fair value range for Thermo Fisher Scientific Inc. (TMO) is $430 (bear) to $608 (bull), with a base case of $519.

Thermo Fisher Scientific Inc. (TMO) Valuation

Rating: Slight Underpriced

12-Month Fair Value: $430 – $519 – $608

Confidence: MEDIUM

Thermo Fisher is the gold standard of life sciences tools — 800,000+ products, ~80% recurring revenue, and the PPI Business System that consistently drives margin expansion. At $527, the stock trades 4% above our $507 weighted fair value with neutral near-term R/R (0.88:1) but favorable long-term R/R (1.84:1). The $9.5B Clario acquisition adds $2B+ revenue from FY2027, and bioprocessing recovery is the key near-term catalyst. Three under-the-radar risks — debt refinancing wall, PFAS regulation, and NIH/DOGE cuts — create more downside skew than consensus appreciates.

View full report | All intelligence | Home